Axsome Therapeutics, Inc. (AXSM) News

Axsome Therapeutics, Inc. (AXSM): $112.51

1.49 (-1.31%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add AXSM to Watchlist
Sign Up

Filter AXSM News Items

AXSM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AXSM News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest AXSM News From Around the Web

Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) is possibly approaching a major achievement in its business, so we would like...

Yahoo | January 6, 2025

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation, demonstrating a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint (relapse prevention, p=0.001). Further, AXS-05 reduced the w

Yahoo | December 31, 2024

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Yahoo | December 30, 2024

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, prevention of relapse of Alzheimer’s disease agitation) AXS-05 reduced worsening of Alzheimer’s disease overall compared to placebo in ACCORD-2 Phase 3 trial (p<0.001, CGI-S Alzheimer’s disease overall clinical status) ADVANCE-2 trial did not demonstrate statistical significance on pri

Yahoo | December 30, 2024

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 12, 2024

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial. AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials. The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compar

Yahoo | November 27, 2024

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Yahoo | November 26, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C) Cataplexy response (≥50% improvement) achieved by 72% of patients at 1 month and 82% at 6 months Improvement in excessive daytime sleepiness (EDS), assessed by the CGI-C, achieved by 84% of

Yahoo | November 26, 2024

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.

Yahoo | November 13, 2024

Q3 2024 Axsome Therapeutics Inc Earnings Call

Q3 2024 Axsome Therapeutics Inc Earnings Call

Yahoo | November 13, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!